Efficacy and Safety of Ametinib Combined With Bevacizumab in First-line Treatment of Non-oligometastatic Advanced NSCLC With EGFR-mutations.
To explore the intracranial/extracranial ORR, PFS, QoL, safety, dynamic changes of tissue, cerebrospinal fluid, and plasma DNA in patients with newly diagnosed advanced NSCLC with EGFR mutation with/without brain metastasis given first-line treatment with almonertinib combined with bevacizumab at the initial stage of treatment, during treatment and after drug resistance, and the correlation between early clearance of sensitive mutations and survival.
• Male or female, ≥18 years old and ≤75years old;
⁃ Non-squamous non-small cell lung cancer (NSCLC) confirmed by pathology (including histology or cytology); ③ EGFR mutation positive (exon 19 deletion or exon 21 L858R mutation); (4) ≥3 intracranial metastases, asymptomatic brain metastases; (5) Never received antitumor therapy before;
‣ There was at least 1 measurable intracranial and extracranial lesion in CT/MRI according to RECIST1.1 criteria.
‣ ⑦ Predicted survival ≥3 months;
‣ ⑧ ECOG score 0-1;
‣ ⑨ The main organs (liver, kidney, heart) function normally.
‣ ⑩ Sign informed consent forms.